Mutations in TP53, EZH2, ETV6, RUNX1, and ASXL1 are indicators of poor overall survival in patients with MDS, autonomous of other established risk factors, and SF3B1 mutations confer a better clinical outcome. Here, SF3B1 is linked to myelodysplastic syndrome.